Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-308139

ABSTRACT

Background: During the first wave of the coronavirus (COVID-19) pandemic, restrictive public health measures including prolonged shielding, were recommended by the United Kingdom government for many patients with immune-mediated inflammatory disorders treated with immunosuppressive and biologic drugs. Low-volume intracapillary blood sampling can be undertaken by patients at home and returned by post and may ensure access to therapeutic drug monitoring (TDM) for all patients irrespective of shielding status.Methods: We undertook a cross-sectional blood sampling methods comparison study to assess the clinical validity and acceptability to patients of low volume intracapillary testing for serum TDM enzyme-linked immunosorbent assays (ELISA) compared to conventional venepuncture. Sample types were compared using linear regression and fit-for-purpose equivalence was defined using total allowable error (TEa) rates derived using interassay coefficient of variations from routine clinical practice. Acceptability was assessed using a purpose-designed questionnaire.Findings: The median (IQR) volume of serum obtained using intracapillary sampling was 195µL (130-210). We showed drug level equivalence (slope [95% CI]: TEa vs observed mean % difference) between intracapillary sampling and conventional venepuncture for adalimumab (1·02 [0·90-1·14]: 11·7% vs 2·1%), infliximab (1·08 [0·98-1·18]: 18·3% vs 1·2%), vedolizumab (0·91 [0·85-0·96]: 17·6% vs 4·1%), and ustekinumab (0·92 [0·90-0·94]: 19·4% vs 3·3%). Anti-drug antibody equivalence was observed for anti-adalimumab (0·96 [0·95-0·98]: 24·5% vs 2·1%) and anti-infliximab (0·89 [0·81-0·97]: 17·3% vs 1·3%) antibody levels. Most patients reported that intracapillary testing was easy, convenient, and that they preferred it to conventional venepuncture.Interpretation: Low-volume intracapillary blood sampling was equivalent to conventional venepuncture for the measurement of biologic drug and anti-drug antibodies. Patients preferred intra-capillary testing to conventional venepuncture. Irrespective of future COVID-19 surges, patient-led intracapillary blood sampling is likely to become a key adjunct to telemedicine in patients with immune-mediated inflammatory diseases.Funding: Novo Nordisk Foundation. NIHR Exeter Clinical Research Facility. The Academic Department of Blood Sciences, RDE NHS Trust.Declaration of Interests: All authors have completed the ICMJE Form for Disclosure of Potential Conflicts of Interest and declare: D.C received honoraria from Ferring and Pfizer outside of this work;N.A.K has consulted for Falk and received honoraria from Falk, Allergan, Pharmacosmos and Takeda for unrelated topics and is a deputy editor of Alimentary Pharmacology & Therapeutics Journal;T.A has received unrestricted research grants, advisory board fees, speaker honorariums and support to attend international meetings from AbbVie, Merck, Janssen, Takeda, Ferring, Tillotts, Ferring, Pfizer, NAPP, Celltrion, Hospira for unrelated topics, no financial relationships with any organizations that might have an interest in the submitted work in the previous three years;no other relationships or activities that could appear to have influenced the submitted work. R.N, B.H, E.J, S.H, C.R, V.C, K.P, J.R.G and T.J.M have no conflicts of interest to declare.Ethics Approval Statement: The sponsor was the Royal Devon and Exeter NHS Foundation Trust and the South West Research Ethics Committee approved the study (IRAS Reference Number: 286396;July 2020).

2.
J Crohns Colitis ; 16(2): 190-198, 2022 Feb 23.
Article in English | MEDLINE | ID: covidwho-1319160

ABSTRACT

BACKGROUND AND AIMS: Because of COVID-19 public health restrictions, telemedicine has replaced conventional outpatient follow up for most patients with chronic immune-mediated inflammatory disorders treated with biologic drugs. Innovative solutions to facilitate remote therapeutic drug monitoring are therefore required. Low-volume intracapillary blood sampling can be undertaken by patients at home and samples returned by post to central laboratories. We sought to report the effect of the COVID-19 pandemic on requests for therapeutic drug monitoring and the equivalence, acceptability and effectiveness of low volume Patient-led Remote IntraCapillary pharmacoKinetic Sampling [fingerPRICKS] compared to conventional venepuncture. METHODS: We undertook a cross-sectional blood sampling methods comparison study and compared sample types using linear regression models. Drug and antidrug antibody levels were measured using standard ELISAs. Acceptability was assessed using a purpose-designed questionnaire. RESULTS: Therapeutic drug monitoring requests for adalimumab (96.5 [70.5-106] per week to 52 [33.5-57.0], p < 0.001) but not infliximab (184.5 [161.2-214.2] to 161 [135-197.5], p = 0.34) reduced during the first UK stay-at-home lockdown compared with the preceding 6 months. Fingerprick sampling was equivalent to conventional venepuncture for adalimumab, infliximab, vedolizumab and ustekinumab drug, and anti-adalimumab and anti-infliximab antibody levels. The median [interquartile range] volume of serum obtained using intracapillary sampling was 195 µL [130-210]. More than 87% [90/103] of patients agreed that intracapillary testing was easy and 69% [71/103] preferred it to conventional venepuncture. In routine care, 75.3% [58/77] of patients returned two blood samples within 14 days to permit remote assessment of biologic therapeutic drug monitoring. CONCLUSIONS: Therapeutic drug monitoring can be undertaken using patient-led remote intracapillary blood sampling and has the potential to be a key adjunct to telemedicine in patients with immune-mediated inflammatory diseases.


Subject(s)
Drug Monitoring , Inflammatory Bowel Diseases , Self-Testing , Adalimumab/therapeutic use , COVID-19 , Cross-Sectional Studies , Drug Monitoring/methods , Humans , Inflammatory Bowel Diseases/drug therapy , Infliximab/therapeutic use , Pandemics , SARS-CoV-2 , United Kingdom
3.
Social Education ; 85(2):72-77, 2021.
Article in English | ProQuest Central | ID: covidwho-1308679

ABSTRACT

The goal this article is to describe the economic impact of the COVID-19 pandemic, compare the situation in the United States (U.S.) to that of similar countries, and analyze the actions taken by the U.S. government. The authors chose to compare the U.S. to Canada, the United Kingdom, and Germany as these countries are similar to the U.S. in their economic structure and living standards. The authors hope these perspectives on costs as well as benefits of government action will provide teachers with a more in-depth understanding of the impact of COVID-19 on the U.S. economy.

SELECTION OF CITATIONS
SEARCH DETAIL